The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Open accessAbstract
The abilities of NF-κB to promote cell proliferation, suppress apoptosis, promote cell migration, and suppress differentiation apparently have been co-opted by cellular and viral oncoproteins to promote oncogenesis (Figure 2). Direct evidence, using both in vitro and in vivo models, indicates that NF-κB is required for oncogenesis, probably at multiple levels. NF-κB likely plays an important role in the early events of oncogenesis, possibly functioning primarily in protecting against transformation-associated apoptosis. In most late-stage tumor cells, classic NF-κB (the p50-p65 heterodimer) is clearly not the only survival factor, because its inhibition does not induce apoptosis in many of these tumor cells. This observation suggests that other events have occurred to upregulate NF-κB-independent cell survival pathways. However, clearly some cancer cells depend on NF-κB for their survival. NF-κB also can contribute to cell progression by transcriptionally upregulating cyclin D1 with corresponding hyperphosphorylation of the tumor suppressor protein Rb. The induction of NF-κB-controlled proliferation may correlate with loss of differentiation in certain settings (47), which may promote oncogenesis. NF-κB is known to regulate certain genes associated with metastasis, such as matrix metalloproteinase 9, tissue plasminogen activator, and ICAM-1. Thus, a more relevant role for NF-κB in later-stage oncogenesis may be to promote metastasis and angiogenesis. Although many tumor cells display some level of constitutive nuclear NF-κB, higher levels of NF-κB and the transcriptional potential of NF-κB can be further enhanced in response to certain types of chemotherapy. Consistent with this, inhibition of NF-κB in parallel with certain (but apparently not all) chemotherapy treatments strongly enhances the apoptotic potential of the chemotherapy. This observation indicates that NF-κB plays an important role in inducible chemoresistance and establishes NF-κB inhibition as a new adjuvant approach in chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Self-citationTherapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Self-citationNF-κB-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle Decay and Cachexia
Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C.-Y., & Baldwin Jr., A. S. (2000) · Science · doi:10.1126/science.289.5488.2363 · Cited by 924
Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119849 · Cited by 761
Cited by
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedDavis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 888
The Role of Metallothionein in Oxidative Stress
Ruttkay-Nedecky, B., Nejdl, L., Gumulec, J., Zitka, O., Masarik, M., Eckschlager, T., Stiborova, M., Adam, V., & Kizek, R. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036044 · Cited by 839
Apoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
Weaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis
Kucharczak, J., Simmons, M. J., Fan, Y., & Gélinas, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207230 · Cited by 769
Role of JNK activation in apoptosis: A double-edged sword
LIU, J., & LIN, A. (2005) · Cell Research · doi:10.1038/sj.cr.7290262 · Cited by 738
Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., & Franzoso, G. (2001) · Nature · doi:10.1038/35104560 · Cited by 732
“Activation of NF-κB antagonizes apoptosis or programmed cell death by numerous triggers, including the ligand engagement of ‘death receptors’ such as tumour-necrosis factor (TNF) recepto”
BackgroundChang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Self-citationDevelopment of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Shingo, T., Sorokan, S. T., Shimazaki, T., & Weiss, S. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09733.2001 · Cited by 653
p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637
Ryo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y.-C., Wulf, G., Rottapel, R., Yamaoka, S., & Lu, K. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00490-8 · Cited by 637
Younes, A., Sehn, L. H., Johnson, P., Zinzani, P. L., Hong, X., Zhu, J., Patti, C., Belada, D., Samoilova, O., Suh, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02403 · Cited by 608
Achieving Stability of Lipopolysaccharide-Induced NF-κB Activation
Covert, M. W., Leung, T. H., Gaston, J. E., & Baltimore, D. (2005) · Science · doi:10.1126/science.1112304 · Cited by 603
Multi-targeted prevention of cancer by sulforaphane
Clarke, J. D., Dashwood, R. H., & Ho, E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.018 · Cited by 563
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment
Chikara, S., Nagaprashantha, L. D., Singhal, J., Horne, D., Awasthi, S., & Singhal, S. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.002 · Cited by 559
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Self-citationTaxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
“gression, in addition to being a central coordinator of immune responses.(27,48,49) The viral protein v-rel (homolog of c-rel) was originally identified as retroviral oncogene.”
BackgroundLenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Lefranc, F., Brotchi, J., & Kiss, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.089 · Cited by 526
NF-κB, chemokine gene transcription and tumour growth
Richmond, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri887 · Cited by 523
Nuclear factor-kappa B and cancer: its role in prevention and therapy
Bharti, A. C., & Aggarwal, B. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01154-1 · Cited by 510
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0299fje · Cited by 501
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Therapeutic applications of compounds in the Magnolia family
Lee, Y.-J., Lee, Y. M., Lee, C.-K., Jung, J. K., Han, S. B., & Hong, J. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.010 · Cited by 481
Apoptosis pathways in cancer and cancer therapy
Debatin, K.-M. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0474-8 · Cited by 476
Eferl, R., Ricci, R., Kenner, L., Zenz, R., David, J.-P., Rath, M., & Wagner, E. F. (2003) · Cell · doi:10.1016/s0092-8674(03)00042-4 · Cited by 474
New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation
Chen, F., Castranova, V., & Shi, X. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61708-7 · Cited by 473
Microtubule-targeted anticancer agents and apoptosis
Bhalla, K. N. (2003) · Oncogene · doi:10.1038/sj.onc.1207233 · Cited by 461
Pathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434
Activation of the JNK signaling pathway: Breaking the brake on apoptosis
Lin, A. (2003) · BioEssays · doi:10.1002/bies.10204 · Cited by 432
Fribley, A., Zeng, Q., & Wang, C.-Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9695-9704.2004 · Cited by 424
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Lymphoid Malignancies: the dark side of B-cell differentiation
Shaffer, A. L., Rosenwald, A., & Staudt, L. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri953 · Cited by 419
Molecular Link Mechanisms between Inflammation and Cancer
B. Vendramini-Costa, D., & E. Carvalho, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 417
Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms
Skrajnowska, D., & Bobrowska-Korczak, B. (2019) · Nutrients · doi:10.3390/nu11102273 · Cited by 414
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
Greten, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.029 · Cited by 410
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
NF-κB Signaling Pathway, Inflammation and Colorectal Cancer
Wang, S., Liu, Z., Wang, L., & Zhang, X. (2009) · Cellular & Molecular Immunology · doi:10.1038/cmi.2009.43 · Cited by 405
Tinospora cordifolia: One plant, many roles
Ghosh, S., & Saha, S. (2012) · Ancient Science of Life · doi:10.4103/0257-7941.107344 · Cited by 404
Targeting pathological B cell receptor signalling in lymphoid malignancies
Young, R. M., & Staudt, L. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3937 · Cited by 401
NF-κB and IKK as therapeutic targets in cancer
Kim, H. J., Hawke, N., & Baldwin, A. S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401877 · Cited by 391
Self-citationTwo Waves of Nuclear Factor κb Recruitment to Target Promoters
Saccani, S., Pantano, S., & Natoli, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.12.1351 · Cited by 389
Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects
Reyna, S. M., Ghosh, S., Tantiwong, P., Meka, C. S. R., Eagan, P., Jenkinson, C. P., Cersosimo, E., DeFronzo, R. A., Coletta, D. K., Sriwijitkamol, A., et al. (2008) · Diabetes · doi:10.2337/db08-0038 · Cited by 388
Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB
Campbell, K. J., Rocha, S., & Perkins, N. D. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00131-5 · Cited by 386
NF-κB as a therapeutic target in chronic inflammation: recent advances
Makarov, S. S. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01814-1 · Cited by 379
Sakurai, H., Suzuki, S., Kawasaki, N., Nakano, H., Okazaki, T., Chino, A., Doi, T., & Saiki, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301598200 · Cited by 377
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
The metabolic syndrome: role of skeletal muscle metabolism.
Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. (2006) · Annals of Medicine · doi:10.1080/07853890600888413 · Cited by 362
Tumour necrosis factor α: a potential target for the therapy of solid tumours
Szlosarek, P. W., & Balkwill, F. R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01196-3 · Cited by 355
NF-κB in cancer: a marked target
Lin, A., & Karin, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00128-1 · Cited by 355
A Practical Review of Proteasome Pharmacology
Thibaudeau, T. A., & Smith, D. M. (2019) · Pharmacological Reviews · doi:10.1124/pr.117.015370 · Cited by 344
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Park, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., Gu, K., Shah, V., Pei, L., Zarbo, R. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1519 · Cited by 325
Signals from within: the DNA-damage-induced NF-κB response
Janssens, S., & Tschopp, J. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401843 · Cited by 324
PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling
Su, T. T., Guo, B., Kawakami, Y., Sommer, K., Chae, K., Humphries, L. A., Kato, R. M., Kang, S., Patrone, L., Wall, R., et al. (2002) · Nature Immunology · doi:10.1038/ni823 · Cited by 322
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
PIDD Mediates NF-κB Activation in Response to DNA Damage
Janssens, S., Tinel, A., Lippens, S., & Tschopp, J. (2005) · Cell · doi:10.1016/j.cell.2005.09.036 · Cited by 319
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Self-citationSignatures of the Immune Response
Shaffer, A. L., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Lam, L. T., Pickeral, O. K., & Staudt, L. M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00194-7 · Cited by 314
Bidirectional regulation of NF-κB by reactive oxygen species: A role of unfolded protein response
Nakajima, S., & Kitamura, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.020 · Cited by 307
Modulation of NF-κB Activity by Exchange of Dimers
Saccani, S., Pantano, S., & Natoli, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00227-2 · Cited by 301
Signaling Molecules of the NF-κB Pathway Shuttle Constitutively between Cytoplasm and Nucleus
Birbach, A., Gold, P., Binder, B. R., Hofer, E., de Martin, R., & Schmid, J. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112475200 · Cited by 299
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 293
Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65
Lu, T., Jackson, M. W., Wang, B., Yang, M., Chance, M. R., Miyagi, M., Gudkov, A. V., & Stark, G. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912493107 · Cited by 280
Lee, H., Kim, Y. O., Kim, H., Kim, S. Y., Noh, H. S., Kang, S. S., Cho, G. J., Choi, W. S., & Suk, K. (2003) · The FASEB Journal · doi:10.1096/fj.03-0057fje · Cited by 278
NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy
Shen, H.-M., & Tergaonkar, V. (2009) · Apoptosis · doi:10.1007/s10495-009-0315-0 · Cited by 275
A Genetically Defined Model for Human Ovarian Cancer
Liu, J., Yang, G., Thompson-Lanza, J. A., Glassman, A., Hayes, K., Patterson, A., Marquez, R. T., Auersperg, N., Yu, Y., Hahn, W. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3380 · Cited by 273
Nuclear factor-κB is upregulated in colorectal cancer
Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M., & MacKay, S. (2001) · Surgery · doi:10.1067/msy.2001.116672 · Cited by 269
Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., & Scheidereit, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020062 · Cited by 266
Positive and Negative Regulation of NF-κB by COX-2
Poligone, B., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106599200 · Cited by 263
Self-citationNF-κB: tumor promoter or suppressor?
Perkins, N. D. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2003.12.004 · Cited by 261
NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells
Brar, S. S., Corbin, Z., Kennedy, T. P., Hemendinger, R., Thornton, L., Bommarius, B., Arnold, R. S., Whorton, A. R., Sturrock, A. B., Huecksteadt, T. P., et al. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00525.2002 · Cited by 260
Wang, H., Hertlein, E., Bakkar, N., Sun, H., Acharyya, S., Wang, J., Carathers, M., Davuluri, R., & Guttridge, D. C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02020-06 · Cited by 259
COMMD Proteins, a Novel Family of Structural and Functional Homologs of MURR1
Burstein, E., Hoberg, J. E., Wilkinson, A. S., Rumble, J. M., Csomos, R. A., Komarck, C. M., Maine, G. N., Wilkinson, J. C., Mayo, M. W., & Duckett, C. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501928200 · Cited by 258
Hamid, T., Guo, S. Z., Kingery, J. R., Xiang, X., Dawn, B., & Prabhu, S. D. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq274 · Cited by 252
Multitargeted therapy of cancer by ellagitannins
Heber, D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.043 · Cited by 227
Metadata
- Authors
- Baldwin, A. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 241-246
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2051994734
- Cited by
- 1,434
- References
- 45
- FWCI
- 40.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.